GSK's Shingrix vaccine increases dementia-free period by 164 days compared to Merck's Zostavax, crucial in combating dementia, a global challenge affecting over 55 million people.
Study indicates potential protective mechanisms of vaccines against dementia, such as virus reduction or influencing disease pathways, vital for understanding and developing future interventions.
Shingrix shows stronger dementia-delaying effects in women compared to men, indicating gender-specific responses to the vaccine, a critical finding for personalized healthcare approaches.
Collection
[
|
...
]